Hillsdale Investment Management Inc. Takes $7.13 Million Position in MiMedx Group, Inc $MDXG

Hillsdale Investment Management Inc. acquired a new position in MiMedx Group, Inc (NASDAQ:MDXG) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,053,800 shares of the company’s stock, valued at approximately $7,134,000. Hillsdale Investment Management Inc. owned 0.71% of MiMedx Group at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Legato Capital Management LLC boosted its holdings in MiMedx Group by 18.5% in the third quarter. Legato Capital Management LLC now owns 17,341 shares of the company’s stock valued at $121,000 after acquiring an additional 2,708 shares during the last quarter. SkyView Investment Advisors LLC boosted its holdings in MiMedx Group by 3.6% in the second quarter. SkyView Investment Advisors LLC now owns 87,734 shares of the company’s stock valued at $523,000 after acquiring an additional 3,032 shares during the last quarter. Rafferty Asset Management LLC boosted its holdings in MiMedx Group by 5.2% in the third quarter. Rafferty Asset Management LLC now owns 66,240 shares of the company’s stock valued at $462,000 after acquiring an additional 3,262 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in MiMedx Group by 5.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 73,518 shares of the company’s stock valued at $559,000 after acquiring an additional 4,049 shares during the last quarter. Finally, AQR Capital Management LLC boosted its holdings in MiMedx Group by 42.6% in the first quarter. AQR Capital Management LLC now owns 14,374 shares of the company’s stock valued at $109,000 after acquiring an additional 4,296 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors.

MiMedx Group Price Performance

Shares of MDXG opened at $3.68 on Friday. MiMedx Group, Inc has a 52-week low of $3.03 and a 52-week high of $7.99. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.81 and a current ratio of 5.39. The business’s 50 day moving average price is $3.70 and its two-hundred day moving average price is $5.17. The firm has a market cap of $548.14 million, a PE ratio of 18.40 and a beta of 1.46.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings results on Wednesday, April 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.02. MiMedx Group had a return on equity of 21.03% and a net margin of 7.88%.The firm had revenue of $58.99 million for the quarter, compared to analyst estimates of $65.80 million. On average, equities analysts anticipate that MiMedx Group, Inc will post -0.01 EPS for the current year.

Analyst Ratings Changes

Several analysts recently commented on the company. Craig Hallum reduced their target price on MiMedx Group from $10.00 to $7.00 and set a “buy” rating on the stock in a report on Friday, April 17th. Citizens Jmp reduced their target price on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating on the stock in a report on Thursday, April 30th. Citigroup assumed coverage on MiMedx Group in a report on Monday, February 23rd. They issued a “market outperform” rating on the stock. UBS Group set a $10.00 target price on MiMedx Group in a report on Monday, February 23rd. Finally, Wall Street Zen cut MiMedx Group from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, MiMedx Group currently has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.